文献速递创伤骨科骨质疏松与代谢性骨病

髋部骨折患者的合并症与感染风险:一项丹麦人群队列研究

Comorbidity and risk of infection among patients with hip fracture: a Danish population-based cohort study.
PubMed 文献 · Osteoporos Int · 2023-06-17

该丹麦人群队列研究纳入2004至2018年间92600例65岁及以上接受髋部骨折手术的患者,按Charlson合并症指数分为无、中度(1-2分)和重度(≥3分)三组。结果显示合并症越重,术后1年内感染发生率越高,重度合并症组任何医院治疗感染发生率达37%,脓毒症风险比为2.7。合并症是髋部骨折术后1年内感染的重要危险因素。

要点

  • 重度合并症组术后0-365天任何医院治疗感染发生率为37%,无合并症组为22%。
  • 重度合并症组术后0-365天脓毒症风险比为2.7(CI: 2.4-2.9),为各项感染中最高。
  • 中度与重度合并症组术后0-365天任何医院治疗感染风险比分别为1.4和1.9。

核心结论

  • 合并症是髋部骨折手术后1年内感染的重要危险因素。

研究设计与样本

  • 利用丹麦人群医学登记数据库,识别2004至2018年间92600例65岁及以上接受髋部骨折手术的患者。
  • 按Charlson合并症指数评分将合并症分为无(CCI=0)、中度(CCI=1-2)、重度(CCI≥3)三组。
  • 主要结局为任何医院治疗感染;次要结局包括医院治疗肺炎、尿路感染、脓毒症、手术部位感染所致再手术及任何医院或社区治疗感染的复合结局。
  • 计算累积发生率和校正年龄、性别及手术年份的风险比(aHR)及95%置信区间(CI)。

主要发现

  • 中度合并症患病率为40%,重度为19%。
  • 任何医院治疗感染发生率在0-30天:无合并症组13% vs 重度合并症组20%;在0-365天:无合并症组22% vs 重度合并症组37%。
  • 中度与重度合并症组相比无合并症组,0-30天任何医院治疗感染的aHR分别为1.3(CI: 1.3-1.4)和1.6(CI: 1.5-1.7)。
  • 中度与重度合并症组相比无合并症组,0-365天任何医院治疗感染的aHR分别为1.4(CI: 1.4-1.5)和1.9(CI: 1.9-2.0)。
  • 0-365天内任何医院或社区治疗感染发生率最高(重度合并症组72%);0-365天内脓毒症的aHR最高(重度 vs 无:2.7(CI: 2.4-2.9))。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Impact of comorbidity on infection risk among hip fracture patients is unclear. We found high incidence of infection. Comorbidity was an important risk factor for infection up to 1 year after surgery. Results indicates a need for additional investment in pre- and postoperative programs that assist patients with high comorbidity. PURPOSE: Comorbidity level and incidence of infection have increased among older patients with hip fracture. The impact of comorbidity on infection risk is unclear. We conducted a cohort study examining the absolute and relative risks of infection in relation to comorbidity level among hip fracture patients. METHODS: Utilizing Danish population-based medical registries, we identified 92,600 patients aged ≥ 65 years undergoing hip fracture surgery between 2004 and 2018. Comorbidity was categorized by Charlson comorbidity index scores (CCI): none (CCI = 0), moderate (CCI = 1-2), or severe (CCI ≥ 3). Primary outcome was any hospital-treated infection. Secondary outcomes were hospital-treated pneumonia, urinary tract infection, sepsis, reoperation due to surgical-site infection (SSI), and a composite of any hospital- or community-treated infection. We calculated cumulative incidence and hazard ratios (aHRs) adjusted for age, sex, and surgery year, including 95% confidence intervals (CIs). RESULTS: Prevalence of moderate and severe comorbidity was 40% and 19%, respectively. Incidence of any hospital-treated infection increased with comorbidity level within 0-30 days (none 13% vs. severe 20%) and 0-365 days (none 22% vs. 37% severe). Patients with moderate and severe comorbidity, compared to no comorbidity, had aHRs of 1.3 (CI: 1.3-1.4) and 1.6 (CI: 1.5-1.7) within 0-30 days, and 1.4 (CI: 1.4-1.5) and 1.9 (CI: 1.9-2.0) within 0-365, respectively. Highest incidence was observed for any hospital- or community-treated infection (severe 72%) within 0-365 days. Highest aHR was observed for sepsis within 0-365 days (severe vs. none: 2.7 (CI: 2.4-2.9)). CONCLUSION: Comorbidity is an important risk factor for infection up to 1 year after hip fracture surgery.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Gadgaard NR, Varnum C, Nelissen RGHH, et al. Comorbidity and risk of infection among patients with hip fracture: a Danish population-based cohort study. Osteoporos Int. 2023. PMID: 37330437. doi:10.1007/s00198-023-06823-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。